Overview

• The AI test developed by Artera and trialled by The Institute of Cancer Research and UCL analyses tumour biopsy images to detect biomarkers invisible to the human eye.
• In a trial of over 1,000 men with high-risk non-metastatic prostate cancer, biomarker-positive patients saw their five-year death risk cut from 17% to 9% when given abiraterone.
• The NHS in England currently does not fund abiraterone for this patient group, creating a regional disparity with Scotland and Wales where the drug is available.
• With abiraterone priced at £77 per pack since its 2022 patent expiry, targeting treatment could be cost-effective for roughly 2,100 men annually.
• Leading researchers and patient advocates are urging NHS England and the Department of Health and Social Care to expand funding now that the AI test can identify who benefits most.